Oseltamivir
اسلتامیویر
🦠 Antiinfectives For Systemic UseNeuraminidase inhibitor
Market / country: 🇺🇸 USA
Tamiflu (US)
🧮 Dose calculator
Influenza (flu) · Regimen source: FDA Oseltamivir susp · 2.2, Table 1
- • Start within 48 hours of symptom onset; 5 days. Better tolerated with food. FDA Oseltamivir susp · 2.2FDA Oseltamivir susp · 2.1
Enter age and weight.
🛡️ Safety & information
Contraindications
- ⛔ Known serious hypersensitivity to oseltamivir. FDA Oseltamivir susp · 4
Warnings
- • Serious skin/hypersensitivity reactions FDA Oseltamivir susp · 5.1
- • Neuropsychiatric events; monitor the patient. FDA Oseltamivir susp · 5.2
Renal adjustment
- • eGFR < 60: CrCl ≤60 mL/min: reduce dose per Table 2 (adults). FDA Oseltamivir susp · 2.4
Formulations
- 6 mg / mL — suspension 🇺🇸 USA FDA Oseltamivir susp · 3
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Oseltamivir susp · 8.1
“Risk Summary There are no adequate and well-controlled studies with oseltamivir phosphate for oral suspension in pregnant women to inform a drug‐associated risk of adverse developmental outcomes.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Oseltamivir susp · 8.2
“Risk Summary Based on limited published data, oseltamivir and oseltamivir carboxylate have been shown to be present in human milk at low levels considered unlikely to lead to toxicity in the breastfed infant.”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Oseltamivir susp · 8.4
“Treatment of Influenza The safety and efficacy of oseltamivir phosphate for the treatment of influenza in pediatric patients 2 weeks old to 17 years of age has been established [see Dosage and Administration ( 2.2 ), Clinical Pharmacology (12.3), and Clinical Studies ( 14.1 )] and is based on: 13 to 17 years of age: …”
- 👴 Older adultsNo specific problem stated
Label: no specific difference or dose adjustment stated for older adults. FDA Oseltamivir susp · 8.5
“… tients at least 65 years old, that enrolled 741 subjects (374 received placebo and 362 received oseltamivir phosphate), no overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses …”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)ANDA208823
- DailyMed (FDA label)FDA Oseltamivir susp
- MedlinePlus (NIH)Oseltamivir
- WHO ATC/DDDJ05AH02
- Darooyab (Iran)Oseltamivir
🇮🇷 Registered in Iran Darooyab · G-1192/Oseltamivir
Dosage forms with Iranian generic codes, per Darooyab.
- 17745 · OSELTAMIVIR 30MG CAP · کپسول اسلتامیویر ۳۰ میلیگرم
- 17746 · OSELTAMIVIR 45MG CAP · کپسول اسلتامیویر ۴۵ میلیگرم
- 21674 · OSELTAMIVIR 60MG/5ML POWDER FOR SUSP · پودر برای تهیه سوسپانسیون خوراکی اسلتامیویر ۶۰ میلیگرم / ۵ میلیلیتر
- 07721 · OSELTAMIVIR 60MG/5ML SYRUP · شربت اسلتامیویر ۶۰ میلیگرم / ۵ میلیلیتر
- 05437 · OSELTAMIVIR 75MG CAP · کپسول اسلتامیویر ۷۵ میلیگرم
- 50332 · OSELTAMIVIR (AS PHOSPHATE) POWDER, FOR SOLUTION ORAL 30 mg/5mL 100 mL · محلول خوراکی اسلتامیویر (معادل فسفات) ۳۰ میلیگرم / ۵ میلیلیتر ۱۰۰ میلیلیتر
- 52806 · OSELTAMIVIR (AS PHOSPHATE) POWDER, FOR SOLUTION ORAL 30 mg/5mL 60 mL · محلول خوراکی اسلتامیویر (معادل فسفات) ۳۰ میلیگرم / ۵ میلیلیتر ۶۰ میلیلیتر
- 51520 · OSELTAMIVIR (AS PHOSPHATE) POWDER, FOR SUSPENSION ORAL 60 mg/5mL 75 mL · سوسپانسیون خوراکی اسلتامیویر (معادل فسفات) ۶۰ میلیگرم / ۵ میلیلیتر ۷۵ میلیلیتر
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Oseltamivir susp · 3FDA Oseltamivir susp · 2.2, Table 1FDA Oseltamivir susp · 2.2FDA Oseltamivir susp · 2.1FDA Oseltamivir susp · 2.3FDA Oseltamivir susp · 4FDA Oseltamivir susp · 5.1FDA Oseltamivir susp · 5.2FDA Oseltamivir susp · 2.4FDA Oseltamivir susp · 8.1FDA Oseltamivir susp · 8.2FDA Oseltamivir susp · 8.4FDA Oseltamivir susp · 8.5FDA Oseltamivir susp · SPL approval / marketing category
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-1192/Oseltamivir
- Clinical review⚠ Unverified